| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 09.05.
| Small Biotechs Like Aastrom Biosciences and Geron Likely to Benefit From New Patent System / Five Star Equities Provides Stock Research on Aastrom Biosciences and Geron | | 53 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 05/09/12 -- In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation. As large pharmaceuticals face major...
Mehr lesen zu:
Small Biotechs Like Aastrom Biosciences and Geron Likely to Benefit From New Patent System / Five Star Equities Provides Stock Research on Aastrom Biosciences and Geron | |
| 02.05.
| Shares of Aastrom Biosciences Rank the Highest in Terms of Price to Forward Sales in the Biotechnology Industry | | 11 | SmarTrend |
| 24.04.
| Aastrom Biosciences Spokesperson Comments on Monday's Option Activity | | 9 | Benzinga.com |
| 20.04.
| Traders Get Bullish on Shares of Aastrom Biosciences, Shares Up 7.6% | | 7 | SmarTrend |
| 10.04.
| JOBS Act Allows Emerging Biotech Companies to Focus Funding on Research / Five Star Equities Provides Stock Research on Aastrom Biosciences, Inc. and StemCells, Inc. | | 49 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 04/10/12 -- One major problems in recent years for emerging biotech companies has been funding for research. With the signing of the Jumpstart Our Business Startups...
Mehr lesen zu:
JOBS Act Allows Emerging Biotech Companies to Focus Funding on Research / Five Star Equities Provides Stock Research on Aastrom Biosciences, Inc. and StemCells, Inc. | |
| 09.04.
| Exclusive Video Q&A With Timothy M. Mayleben, CEO of Aastrom Biosciences | | 41 | MarketWire |
| LOS ANGELES, CA -- (Marketwire) -- 04/09/12 -- Last month, Aastrom Biosciences, Inc. (NASDAQ: ASTM) announced that it had completed an impressive, $40 million private placement financing. The development...
Mehr lesen zu:
Exclusive Video Q&A With Timothy M. Mayleben, CEO of Aastrom Biosciences | |
| 09.03.
| Aastrom (ASTM) Closes Financing with Eastern Capital; Stock Issued at $3,250/Share | | 9 | StreetInsider.com |
| 05.03.
| BioTime and Aastrom Biosciences -- Stem Cell Research Making Breakthroughs / Five Star Equities Provides Stock Research on BioTime & Aastrom Biosciences | | 57 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 03/05/12 -- February was a challenging month for stem cell stocks. TickerSpy's Stem Cell Stocks Index (RXSTM) has slipped nearly 13 percent over the last month -- underperforming...
Mehr lesen zu:
BioTime and Aastrom Biosciences -- Stem Cell Research Making Breakthroughs / Five Star Equities Provides Stock Research on BioTime & Aastrom Biosciences | |
| 24.01.
| Breakthrough Therapy Using Cord Blood Banking Driving Stem Cell Industry / Five Star Equities Provides Stock Research on Cord Blood America & Aastrom Biosciences | | 115 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 01/24/12 -- Given some positive trends, the stem cell market could be set to skyrocket this year. A recent report from Kalorama Information titled "Worldwide Markets...
Mehr lesen zu:
Breakthrough Therapy Using Cord Blood Banking Driving Stem Cell Industry / Five Star Equities Provides Stock Research on Cord Blood America & Aastrom Biosciences | |
| 09.01.
| Stem Cell Therapy From Aastrom Biosciences and Cytori Therapeutics Looks to Gain Ground in 2012 / The Paragon Report Provides Equity Research on Aastrom Biosciences & Cytori Therapeutics | | 118 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 01/09/12 -- Stem Cell stocks -- particularly companies focused on adult stems cells -- have performed well of late. Earlier this month Goldman Sachs noted the potential...
Mehr lesen zu:
Stem Cell Therapy From Aastrom Biosciences and Cytori Therapeutics Looks to Gain Ground in 2012 / The Paragon Report Provides Equity Research on Aastrom Biosciences & Cytori Therapeutics | |
